16
2021-05
Kintor Appointed Dr. Qun Lu as CTO and Dr. Jiawen Han as BD VP
Suzhou, China, May 16, 2021 —真人直营投注网站 (HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced the appointment of Dr. Qun Lu as the Chief Technology Officer (CTO) and Dr. Jiawen Han as vice president of business development. Dr. Lu will be primarily responsible for Chemistry, Manufacturing, and Control (the “CMC”) including drug analysis, formulation development and the production. Dr. Han will be primarily responsible for business development-related projects and management. Both of Dr. Lu and Dr. Han will be reporting to Dr. Youzhi Tong, Founder, Chairman, and CEO of Kintor Pharmaceuticals.
30
2021-04
Kintor Has Expanded Its Geographical Presence to Zhuhai
Zhuhai, China, Apr.30, 2021--真人直营投注网站 announced today that the company has expanded geographical presence to Zhuhai, Guangdong Province (“Zhuhai office”).
25
2021-04
Suzhou, China, April.25, 2021 — 真人直营投注网站 (HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the phase III clinical trial of proxalutamide for the treatment of male patients with mild or moderate COVID-19 symptoms in the United States has completed the first patient enrollment and dosing.
16
2021-04
SUZHOU, China, Apr 16, 2021--真人直营投注网站, a clinical-stage biotechnology company developing small molecule and biological therapeutics, announced today the clinical trial of Pyrilutamide as a treatment for the acne vulgaris has completed the first batch of patients enrolment and successfully dosed in China.
15
2021-04
Suzhou, Apr.15, 2021--真人直营投注网站, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that it has received approval from the National Medical Products Administration to begin clinical trials for GT20029 (gel/tincture) for the treatment of acne and androgenetic alopecia.
12
2021-04
Suzhou, Apr.12, 2021--真人直营投注网站 (stock code 9939.HK, “Kintor Pharmaceutical” or the “Company”), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced a strategic partnership with Hainan Visum Pharmaceutical Limited (“Visum”) to expand proxalutamide manufacturing.
Find Us
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn